BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 15172984)

  • 1. Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker.
    Wreesmann VB; Sieczka EM; Socci ND; Hezel M; Belbin TJ; Childs G; Patel SG; Patel KN; Tallini G; Prystowsky M; Shaha AR; Kraus D; Shah JP; Rao PH; Ghossein R; Singh B
    Cancer Res; 2004 Jun; 64(11):3780-9. PubMed ID: 15172984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Papillary thyroid carcinoma tall cell variant shares accumulation of mitochondria, mitochondrial DNA mutations, and loss of oxidative phosphorylation complex I integrity with oncocytic tumors.
    Tsybrovskyy O; De Luise M; de Biase D; Caporali L; Fiorini C; Gasparre G; Carelli V; Hackl D; Imamovic L; Haim S; Sobrinho-Simões M; Tallini G
    J Pathol Clin Res; 2022 Mar; 8(2):155-168. PubMed ID: 34792302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy.
    Siraj AK; Bavi P; Abubaker J; Jehan Z; Sultana M; Al-Dayel F; Al-Nuaim A; Alzahrani A; Ahmed M; Al-Sanea O; Uddin S; Al-Kuraya KS
    J Pathol; 2007 Oct; 213(2):190-9. PubMed ID: 17703498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MUC1 mucin gene, transcripts, and protein in adenomas and papillary carcinomas of the thyroid.
    Bièche I; Ruffet E; Zweibaum A; Vildé F; Lidereau R; Franc B
    Thyroid; 1997 Oct; 7(5):725-31. PubMed ID: 9349575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cytoplasmic expression of MUC1 in papillary thyroid carcinoma of different histological variants and its correlation with cyclin D1 overexpression.
    Abrosimov A; Saenko V; Meirmanov S; Nakashima M; Rogounovitch T; Shkurko O; Lushnikov E; Mitsutake N; Namba H; Yamashita S
    Endocr Pathol; 2007; 18(2):68-75. PubMed ID: 17916995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression and clinical significance of Muc1, p63 protein in diffuse sclerosing variant of papillary thyroid carcinoma and conventional papillary thyroid carcinoma].
    Hao Y; Jin C; Wang J
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2013 May; 27(9):457-61. PubMed ID: 23898609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of tall cell variant histology on predicting relapse and changing the management of papillary thyroid carcinoma patients.
    Gunalp B; Okuyucu K; Ince S; Ayan A; Alagoz E
    Hell J Nucl Med; 2017; 20(2):122-127. PubMed ID: 28697188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do aggressive variants of papillary thyroid carcinoma have worse clinical outcome than classic papillary thyroid carcinoma?
    Song E; Jeon MJ; Oh HS; Han M; Lee YM; Kim TY; Chung KW; Kim WB; Shong YK; Song DE; Kim WG
    Eur J Endocrinol; 2018 Sep; 179(3):135-142. PubMed ID: 29875289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
    Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
    Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tall cell and diffuse sclerosing variants of papillary thyroid cancer: outcome and predicting value of risk stratification methods.
    Russo M; Malandrino P; Moleti M; Vermiglio F; Violi MA; Marturano I; Minaldi E; Vigneri R; Pellegriti G; Regalbuto C
    J Endocrinol Invest; 2017 Nov; 40(11):1235-1241. PubMed ID: 28528434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic features and prognostic factors of tall cell variant of papillary thyroid carcinoma: comparison with classic variant of papillary thyroid carcinoma.
    Okuyucu K; Alagoz E; Arslan N; Emer O; Ince S; Deveci S; Ayan A; Taslipinar A; Gunalp B; Azal O
    Nucl Med Commun; 2015 Oct; 36(10):1021-5. PubMed ID: 26225942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Papillary thyroid carcinoma tall cell variant.
    Ghossein R; Livolsi VA
    Thyroid; 2008 Nov; 18(11):1179-81. PubMed ID: 18925842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of the clinicopathological features and prognoses of the classical and the tall cell variant of papillary thyroid cancer: a meta-analysis.
    Liu Z; Zeng W; Chen T; Guo Y; Zhang C; Liu C; Huang T
    Oncotarget; 2017 Jan; 8(4):6222-6232. PubMed ID: 28009980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Muc-1 expression may help characterize thyroid nodules but does not predict patients' outcome.
    Morari EC; Silva JR; Guilhen AC; Cunha LL; Marcello MA; Soares FA; Vassallo J; Ward LS
    Endocr Pathol; 2010 Dec; 21(4):242-9. PubMed ID: 21057891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications.
    Ghossein RA; Leboeuf R; Patel KN; Rivera M; Katabi N; Carlson DL; Tallini G; Shaha A; Singh B; Tuttle RM
    Thyroid; 2007 Jul; 17(7):655-61. PubMed ID: 17696836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amplification of thymosin beta 10 and AKAP13 genes in metastatic and aggressive papillary thyroid carcinomas.
    Fehér LZ; Pocsay G; Krenács L; Zvara A; Bagdi E; Pocsay R; Lukács G; Győry F; Gazdag A; Tarkó E; Puskás LG
    Pathol Oncol Res; 2012 Apr; 18(2):449-58. PubMed ID: 22161024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discriminatory miRNAs for the Management of Papillary Thyroid Carcinoma and Noninvasive Follicular Thyroid Neoplasms with Papillary-Like Nuclear Features.
    Jahanbani I; Al-Abdallah A; Ali RH; Al-Brahim N; Mojiminiyi O
    Thyroid; 2018 Mar; 28(3):319-327. PubMed ID: 29378472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The tall cell variant of papillary thyroid carcinoma: clinical and pathological features and outcomes.
    Regalbuto C; Malandrino P; Frasca F; Pellegriti G; Le Moli R; Vigneri R; Pezzino V
    J Endocrinol Invest; 2013 Apr; 36(4):249-54. PubMed ID: 22776915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival of aggressive variants of papillary thyroid carcinoma in patients under 55 years old: a SEER population-based retrospective analysis.
    Feng J; Shen F; Cai W; Gan X; Deng X; Xu B
    Endocrine; 2018 Sep; 61(3):499-505. PubMed ID: 29909599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants.
    Shi X; Liu R; Basolo F; Giannini R; Shen X; Teng D; Guan H; Shan Z; Teng W; Musholt TJ; Al-Kuraya K; Fugazzola L; Colombo C; Kebebew E; Jarzab B; Czarniecka A; Bendlova B; Sykorova V; Sobrinho-Simões M; Soares P; Shong YK; Kim TY; Cheng S; Asa SL; Viola D; Elisei R; Yip L; Mian C; Vianello F; Wang Y; Zhao S; Oler G; Cerutti JM; Puxeddu E; Qu S; Wei Q; Xu H; O'Neill CJ; Sywak MS; Clifton-Bligh R; Lam AK; Riesco-Eizaguirre G; Santisteban P; Yu H; Tallini G; Holt EH; Vasko V; Xing M
    J Clin Endocrinol Metab; 2016 Jan; 101(1):264-74. PubMed ID: 26529630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.